On July 5, the first batch of domestic vaccine and biotechnology ETFs reported by three fund companies and the first batch of traditional Chinese medicine ETFs reported by four fund companies were approved.
Cathay Pacific Fund believes that under the background of the new crown epidemic, the public's awareness of vaccination has been greatly improved, and investment activities in the field of vaccines are also rising rapidly.
Penghua Fund believes that in recent years, the state has vigorously supported the development of traditional Chinese medicines, and the approval criteria for innovative traditional Chinese medicines are constantly being standardized, and the supply-side reform will usher in incremental logic.In addition, traditional Chinese medicine has the attributes of consumer goods and health care products. With the aging of the population and the upgrading of consumption, the traditional Chinese medicine industry has great potential in the future.
According to the investigation, the Vaccine and Biotechnology Index selects 50 sample stocks in the fields of biological products (vaccine, blood products, biological drugs), biological testing, and biotechnology services, including Zhifei Bio (300122), Watson Bio (300142 ), Fosun Pharma (600196) and other companies.The CSI Traditional Chinese Medicine Index selects 50 sample stocks involved in the production and sales of traditional Chinese medicine, including Yiling Pharmaceutical (002603), Zhongsheng Pharmaceutical (002317), Shanghai Kaibao (300039) and other companies.
